"THLD's Phase 3 soft tissue sarcoma trial is likely to play out with topline results by Q3/15 or Q4/15." (1/27/15) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >
"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke More >
"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke More >
Streetwise - The Gold Report, The Energy Report and The Life Sciences Report are Copyright © 2015 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part.
The Gold Report, The Energy Report and The Life Sciences Report do not render general or specific investment advice and do not endorse or recommend the business, products, services or securities of any industry or company mentioned in this report.
From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise. Disclosures for interviewers and experts are listed in individual interviews and are accurate as of the day published.
Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.
Companies listed on the home page in the "Learn More About Companies in this Issue" section pay a flat monthly sponsorship fee. There are no specific performance expectations in exchange for these fees. Fees fund both sponsor-specific activities and general report activities. Sponsor-specific activities include aggregating content and publishing that content on our site, creating and maintaining specialized company pages, interviewing key management and issuing press releases. The fees also cover the costs for Streetwise Reports to publish sector-specific information in our electronic newsletter and also create content by interviewing experts in the sector. Monthly sponsorship fees range from $1,000 to $3,000 per month. Streetwise Reports LLC does not accept stock for payment of sponsorship fees. Sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.
Participating companies provide the logos used in The Gold Report, The Energy Report and The Life Sciences Report. These logos are trademarks and are the property of the individual companies.
Streetwise Reports LLC
101 Second St., Suite 110
Petaluma, CA 94952
Tel.: (707) 981-8999
Fax: (707) 981-8998
|The Gold Report:||Judy Luther -|
|The Energy Report:||Brandon Fung -|
|The Life Sciences Report:||Brandon Fung -|
"The vote of confidence CTH has received from The Michael J. Fox Foundation is very advantageous." (1/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Daniel Pearlstein More >
"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront." (12/30/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >